Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy

Arthritis Research and Therapy

Volumn 15, Issue 2, 2013, Pages

  Aeberli, Daniel ^a   Schett, Georg ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GLUCOCORTICOID; PREDNISONE;

ADAPTATION; BONE DENSITY; CORTICAL BONE; CORTICOSTEROID THERAPY; EPIPHYSIS; ESTROGEN DEFICIENCY; GEOMETRY; HUMAN; MENOPAUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PERIOSTEUM; REVIEW; RHEUMATOID ARTHRITIS; RIGIDITY; ARTHRITIS, RHEUMATOID; BONE REMODELING; DRUG EFFECTS; FEMALE; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE REMODELING; DIPHOSPHONATES; FEMALE; GLUCOCORTICOIDS; HUMANS; MENOPAUSE; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84875370108     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4180     Document Type: Review

References (68)

1. Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, Schett G. Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 2010, 62:330-339.
2. Kamen DL, Alele JD. Skeletal manifestations of systemic autoimmune diseases. Curr Opin Endocrinol Diabetes Obes 2010, 17:540-545. 10.1097/MED.0b013e328340533d, 20962632.
3. Aeberli D, Eser P, Bonel H, Widmer J, Caliezi G, Varisco PA, Möller B, Villiger PM. Reduced trabecular bone mineral density and cortical thickness accompanied by increased outer bone circumference in metacarpal bone of rheumatoid arthritis patients: a cross-sectional study. Arthritis Res Ther 2010, 12:R119. 10.1186/ar3056, 2911913, 20565921.
4. Eser P, Aeberli D, Widmer J, Möller B, Villiger PM. Abnormal bone geometry at the metacarpal bone shaft of rheumatoid arthritis patients with maintained muscle-bone relationship. Arthritis Care Res (Hoboken) 2011, 63:383-389. 10.1002/acr.20541, 21080350.
5. Kay LJ, Holland TM, Platt PN. Stress fractures in rheumatoid arthritis: a case series and case-control study. Ann Rheum Dis 2004, 63:1690-1692. 10.1136/ard.2003.010322, 1754845, 15547098.
6. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, . American Society for Bone and Mineral Research Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294. 10.1002/jbmr.253, 20842676, American Society for Bone and Mineral Research.
7. Mäenpää HM, Soini I, Lehto MU, Belt EA. Insufficiency fractures in patients with chronic inflammatory joint diseases. Clin Exp Rheumatol 2002, 20:77-79.
8. Girgis CM, Sher D, Seibel MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010, 362:1848-1849. 10.1056/NEJMc0910389, 20463351.
9. Seeman E. The growth and age-related origins of bone fragility in men. Calcif Tissue Int 2004, 75:100-109.
10. Parfitt AM. The two faces of growth: benefits and risks to bone integrity. Osteoporos Int 1994, 4:382-398. 10.1007/BF01622201, 7696836.
11. Ruff CB, Hayes WC. Subperiosteal expansion and cortical remodeling of the human femur and tibia with aging. Science 1982, 217:945-948. 10.1126/science.7112107, 7112107.
12. Ruff CB, Hayes WC. Sex differences in age-related remodeling of the femur and tibia. J Orthop Res 1988, 6:886-896. 10.1002/jor.1100060613, 3171769.
13. Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK. Bone loss and bone size after menopause. N Engl J Med 2003, 349:327-334. 10.1056/NEJMoa022464, 12878739.
14. Riggs BL, Wahner HW, Melton LJ, Richelson LS, Judd HL, Offord KP. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest 1986, 77:1487-1491. 10.1172/JCI112462, 424550, 3700651.
15. Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, Amin S, Rouleau PA, Khosla S. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res 2008, 23:205-214. 2665699, 17937534.
16. Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res 1990, 5:311-319. 10.1002/jbmr.5650050402, 2343771.
17. Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261. 10.1056/NEJMra053077, 16723616.
18. Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010, 95:3569-3577. 10.1210/jc.2010-0856, 2913030, 20685883.
19. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000, 21:115-137. 10.1210/er.21.2.115, 10782361.
20. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002, 57:385-409. 10.1210/rp.57.1.385, 12017554.
21. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207-227. 10.1111/j.0105-2896.2005.00334.x, 16313351.
22. Vedi S, Purdie DW, Ballard P, Bord S, Cooper AC, Compston JE. Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy. Osteoporos Int 1999, 10:52-58. 10.1007/s001980050194, 10501780.
23. Szulc P, Seeman E, Duboeuf F, Sornay-Rendu E, Delmas PD. Bone fragility: failure of periosteal apposition to compensate for increased endocortical resorption in postmenopausal women. J Bone Miner Res 2006, 21:1856-1863. 10.1359/jbmr.060904, 17002580.
24. Stein EM, Liu XS, Nickolas TL, Cohen A, Thomas V, McMahon DJ, Zhang C, Yin PT, Cosman F, Nieves J, Guo XE, Shane E. Abnormal microarchitecture and reduced stiffness at the radius and tibia in postmenopausal women with fractures. J Bone Miner Res 2010, 25:2572-2581. 10.1002/jbmr.152, 3149820,3149820, 20564238.
25. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, . Women's Health Initiative Investigators Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003, 290:1729-1738. 10.1001/jama.290.13.1729, 14519707, Women's Health Initiative Investigators.
26. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998, 152:943-951. 1858257, 9546355.
27. Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 1993, 306:558. 10.1136/bmj.306.6877.558, 1677176, 8461772.
28. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population based cohort study. Ann Intern Med 2000, 133:795-799.
29. Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BA, Allaart CF, Lems WF. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 2007, 66:1508-1512. 10.1136/ard.2007.070839, 2111640, 17456523.
30. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, . European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008, 19:399-428. 10.1007/s00198-008-0560-z, 2613968, 18266020, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).
31. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397. 10.1007/s00198-007-0543-5, 2267485, 18292978.
32. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A, . National Osteoporosis Guideline Group Case finding for the management of osteoporosis with FRAX-assessment and intervention thresholds for the UK. Osteoporos Int 2008, 19:1395-1408. 10.1007/s00198-008-0712-1, 18751937, National Osteoporosis Guideline Group.
33. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3104-3112. 10.1002/art.22117, 17009229.
34. Russo CR, Lauretani F, Seeman E, Bartali B, Bandinelli S, Di Iorio A, Guralnik J, Ferrucci L. Structural adaptations to bone loss in aging men and women. Bone 2006, 38:112-118. 10.1016/j.bone.2005.07.025, 16242391.
35. Roth J, Linge M, Tzaribachev N, Schweizer R, Kuemmerle-Deschner J. Musculoskeletal abnormalities in juvenile idiopathic arthritis-a 4-year longitudinal study. Rheumatology (Oxford) 2007, 46:1180-1184. 10.1093/rheumatology/kem100, 17500076.
36. Bogoch E, Gschwend N, Bogoch B, Rahn B, Perren S. Juxtaarticular bone loss in experimental inflammatory arthritis. J Orthop Res 1988, 6:648-656. 10.1002/jor.1100060505, 3404321.
37. Bogoch E, Gschwend N, Bogoch B, Rahn B, Perren S. Changes in the metaphysis and diaphysis of the femur proximal to the knee in rabbits with experimentally induced inflammatory arthritis. Arthritis Rheum 1989, 32:617-624. 10.1002/anr.1780320516, 2719732.
38. Yu Y, Xiong Z, Lv Y, Qian Y, Jiang S, Tian Y. In vivo evaluation of early disease progression by X-ray phase-contrast imaging in the adjuvant-induced arthritic rat. Skeletal Radiol 2006, 35:156-164. 10.1007/s00256-005-0026-8, 16249900.
39. Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:537-544. 10.1002/acr.20172, 20391509.
40. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000. 10.1359/jbmr.2000.15.6.993, 10841167.
41. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383-1389. 10.1093/rheumatology/39.12.1383, 11136882.
42. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787. 10.1007/s001980200108, 12378366.
43. Marshal l D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996, 312:1254-1259. 10.1136/bmj.312.7041.1254, 2351094, 8634613.
44. Hayashi K, Yamamoto M, Murakawa Y, Yamauchi M, Kaji H, Yamaguchi T, Sugimoto T. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 2009, 20:1889-1894. 10.1007/s00198-009-0901-6, 19387764.
45. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010, 6:82-88. 10.1038/nrrheum.2009.259, 20125175.
46. Aaron JE, Francis RM, Peacock M, Makins NB. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop Relat Res 1989, 243:294-305.
47. Chappard D, Legrand E, Basle MF, Fromont P, Racineux JL, Rebel A, Audran M. Altered trabecular architecture induced by corticosteroids: a bone histomorphometric study. J Bone Miner Res 1996, 11:676-685.
48. Vedi S, Elkin SL, Compston JE. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif Tissue Int 2005, 77:79-83. 10.1007/s00223-004-0205-y, 16086108.
49. Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993, 119:963-968.
50. Tsugeno H, Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, Ashida K, Mitsunobu F, Tanizaki Y, Shiratori Y. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 2002, 13:650-656. 10.1007/s001980200088, 12181624.
51. Tsugeno H, Nakai M, Okamoto M, Harada S, Mifune T, Mitsunobu F, Ashida K, Hosaki Y, Tanizaki Y, Tsuji T. Bone mineral density in steroid-dependent asthma assessed by peripheral quantitative computed tomography. Eur Respir J 1999, 14:923-927. 10.1034/j.1399-3003.1999.14d32.x, 10573243.
52. Lian KC, Lang TF, Keyak JH, Modin GW, Rehman Q, Do L, Lane NE. Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporos Int 2005, 16:642-650. 10.1007/s00198-004-1736-9, 15455195.
53. Schorlemmer S, Ignatius A, Claes L, Augat P. Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 2005, 37:491-496. 10.1016/j.bone.2005.05.002, 16046208.
54. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, . HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822. 10.1056/NEJMoa067312, 17476007, HORIZON Pivotal Fracture Trial.
55. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, . Scientific dvisory Council of Osteoporosis Canada 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010, 182:1864-1873. 2988535, 20940232, Scientific dvisory Council of Osteoporosis Canada.
56. Lippune r K. Osteoporosis-whom to treat? The importance of FRAX(R) in Switzerland. Ther Umsch 2012, 69:207-213. 10.1024/0040-5930/a000275, 22403115.
57. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns. Osteoporos Int 2010, 21:41-52. 10.1007/s00198-009-1034-7, 19705046.
58. Hansen KE, Wilson HA, Zapalowski C, Fink HA, Minisola S, Adler RA. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2011, 26:1989-1996. 10.1002/jbmr.362, 21721042.
59. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759. 10.1007/s00198-007-0540-8, 18214569.
60. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996, 19:281-290. 10.1016/8756-3282(96)00182-2, 8873969.
61. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589. 10.1359/jbmr.1998.13.4.581, 9556058.
62. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95:1555-1565. 10.1210/jc.2009-1947, 20173017.
63. Kelly MP, Wustrack R, Bauer DC, Palermo L, Burch S, Peters K, Cauley J, Ensrud K, Black D. Incidence of subtrochanteric and diaphyseal fractures in older white women: data from the Study of Osteoporotic Fractures. J Bone Miner Res 2010, 25(Suppl 1):poster presentation FR0355.
64. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353-1362. 10.1007/s00198-008-0805-x, 19066707.
65. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011, 26:553-560. 10.1002/jbmr.233, 3179297,3179297, 20814954.
66. US Food and Drug Administration. , http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm229171.htm
67. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res 2010, 25:2558-2571. 10.1002/jbmr.157, 3179276, 20564242.
68. Tournis S, Samdanis V, Psarelis S, Liakou C, Antoniou J, Georgoulas T, Dontas I, Papaioannou N, Gazi S, Lyritis GP. Effect of rheumatoid arthritis on volumetric bone mineral density and bone geometry, assessed by peripheral quantitative computed tomography in postmenopausal women treated with bisphosphonates. J Rheumatol 2012, 39:1215-1220. 10.3899/jrheum.110579, 22467921.